Core Insights - Genprex, Inc. (NASDAQ: GNPX) has made the Nasdaq top gainers list due to positive preclinical data regarding its lead drug candidate, Reqorsa® Gene Therapy [4][5] - The stock price increased by 204.75%, trading at $0.7695 with a morning high of $1.10 and a trading volume exceeding 643 million shares [4] Company Developments - Genprex's research collaborators are set to present positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston [5] - The preclinical data pertains to the treatment of ALK-EML4 positive non-small cell lung cancer (NSCLC) using Reqorsa® Gene Therapy [5][6] Management Commentary - Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the presentation of positive preclinical data, highlighting the potential of Reqorsa to induce apoptosis in ALK positive lung cancer, particularly affecting young, non-smoking individuals [6]